Holen Sie sich die Stockscreener-App
74.00
1.00%
-0.7111
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$74.71
Offen:
$74.31
24-Stunden-Volumen:
385.70K
Relative Volume:
0.09
Marktkapitalisierung:
$44.06B
Einnahmen:
$5.72B
Nettoeinkommen (Verlust:
$4.17B
KGV:
10.62
EPS:
6.97
Netto-Cashflow:
$490.10M
1W Leistung:
-2.93%
1M Leistung:
+5.70%
6M Leistung:
+5.52%
1J Leistung:
-14.65%
1-Tages-Spanne:
$73.50
$74.66
1-Wochen-Bereich:
$73.50
$76.67
52-Wochen-Spanne:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
74.00 | 44.06B | 5.72B | 4.17B | 490.10M | 6.97 |
|
ABT
Abbott Laboratories
|
134.46 | 230.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.37 | 155.49B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
385.57 | 147.45B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.61 | 112.85B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Pittenger & Anderson Inc. Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
AlphaCentric Advisors LLC Makes New $691,000 Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Baillie Gifford & Co. Buys 498,100 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Has $287,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Position Lessened by Chevy Chase Trust Holdings LLC - MarketBeat
CIBC Asset Management Inc Sells 31,973 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Rhumbline Advisers Sells 37,002 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WD Rutherford LLC Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Holdings Raised by Empower Advisory Group LLC - MarketBeat
First Merchants Corp Has $773,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Leavell Investment Management Inc. Sells 6,450 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Peering Into Edwards Lifesciences's Recent Short Interest - Benzinga
Edwards Lifesciences Co. (NYSE:EW) Director Steven R. Loranger Sells 5,739 Shares - MarketBeat
Vontobel Holding Ltd. Cuts Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences (NYSE:EW) Stock Rating Lowered by Wolfe Research - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $75.00 - MarketBeat
Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences' SWOT analysis: stock faces TAVR headwinds, TMTT potential - Investing.com
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
FY2025 EPS Forecast for Edwards Lifesciences Cut by Analyst - MarketBeat
Capital Advisors Inc. OK Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences (NYSE:EW) Shares Gap Up After Strong Earnings - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Savant Capital LLC - MarketBeat
New York State Teachers Retirement System Sells 42,203 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
26,922 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Asset Planning Inc - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $71.00 at Canaccord Genuity Group - MarketBeat
Edwards Lifesciences (NYSE:EW) Issues FY 2025 Earnings Guidance - MarketBeat
Edwards Lifesciences (NYSE:EW) Releases Q1 2025 Earnings Guidance - MarketBeat
Van ECK Associates Corp Has $12.67 Million Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Morgan Stanley Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Cut to $73.00 by Analysts at Evercore ISI - MarketBeat
Piper Sandler Increases Edwards Lifesciences (NYSE:EW) Price Target to $73.00 - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Call Transcript - MSN
Edwards Lifesciences (NYSE:EW) Issues Earnings Results - MarketBeat
AustralianSuper Pty Ltd Has $197.57 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Bogart Wealth LLC Increases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 6,500 Shares - MarketBeat
Edwards Lifesciences Director Sells Shares - TradingView
Barclays Increases Edwards Lifesciences (NYSE:EW) Price Target to $90.00 - MarketBeat
Insider Unloading: LESLIE HEISZ STONE Sells Options, Realizes $179K - Benzinga
Ingalls & Snyder LLC Sells 3,463 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Entropy Technologies LP Sells 17,004 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Executives at Edwards Lifesciences Corp Execute Stock Transactions - TradingView
Earnings call transcript: Edwards Lifesciences Q4 2024 beats estimates, stock surges - MSN
Daiwa Adjusts Price Target on Edwards Lifesciences to $77 From $72, Maintains Neutral Rating - Marketscreener.com
Royal Bank of Canada Reaffirms Outperform Rating for Edwards Lifesciences (NYSE:EW) - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):